Startseite Kongressberichte & Archiv 24th Congress of EHA Late-breaking oral presentations (6 best abstracts)

Paolo Ghia, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, et al.

ASCEND PHASE 3 STUDY OF ACALABRUTINIB VS INVESTIGATOR’S CHOICE OF RITUXIMAB PLUS IDELALISIB (IDR) OR BENDAMUSTINE (BR) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Conclusion: Acalabrutinib monotherapy significantly improved PFS with a more tolerable safety profile compared with IdR/BR in pts with R/R CLL.

 

Suzanne Verlhac, Catherine Paillard, Charlotte Jubert, Marie Petras, et al.

IN STROKE-FREE CHILDREN WITH SICKLE CELL ANEMIA AND CEREBRAL VASCULOPATHY, THE OUTCOME OF STENOSIS WAS SIGNIFICANTLY BETTER AFTER TRANSPLANTATION THAN ON CHRONIC TRANSFUSION IN A PROSPECTIVE TRIAL

Conclusion: This prospective trial comparing the outcome of stenosis in stroke-free SCA-patients with history of abnormal-TCD shows a significantly better outcome after SCT than on chronic transfusion encouraging to early systematically recommend SCT in those with stenosis and a MSD.

 

Hitoshi Takizawa, Yoshikazu Hayashi, Maiko Sezaki, Sumit Sheoran, et al.

Conclusion: Our findings suggest that in response to intestinal damage, BM hematopoiesis sense microbiota via innate immune receptor, and induce HSPC expansion followed by directional MPP migration to inflamed lymphoid tissues and generation of myeloid cells specialized for intestinal tissue repair. Uncovering the underlying mechanism for gut-associated inflammation will help to understand inflammatory feedback signals through cross-organ communications that tailor hematopoiesis for tissue surveillance and repair, and might be highly relevant to ageing-associated chronic disorders

 

Cécile Lopez, Esteve Noguera, Vaya Stavropoulou, Zakia Aid, et al.

ONTOGENIC CHANGES IN HEMATOPOIETIC HIERARCHY DETERMINES PEDIATRIC SPECIFICITY AND DISEASE PHENOTYPE IN FUSION ONCOGENE-DRIVEN MYELOID LEUKEMIA

Conclusion:  By integrated analysis of patient samples and transgenic mouse models, we showed that aggressiveness and phenotypes in pediatric AML result from ontogeny-related differential susceptibility to transformation by several fusion oncogenes, which also provides a basis for the higher prevalence of AMKL in pediatric patients. These data also nourish the perspective that direct targeting of the fusion would alter leukemia maintenance and restore a multilineage differentiation potential.

 

Petra Langerbeins, Jasmin Bahlo, Christina Rhein, Henrik Gerwin, et al.

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EALRY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL

Conclusion: The results of this study allow to conclude that ibrutinib significantly improves EFS, PFS and TTNT in patients with treatment-naïve early stage CLL when compared to placebo. There were no significant differences in adverse events between both study arms.

 

Shaji Kumar, Simon Harrison, Michele Cavo, Javier de la Rubia, et al.

A PHASE 3 STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Conclusion: Although the addition of Ven to Bd significantly improved PFS, ORR, ≥VGPR, and uMRD rates, the increased risk of death results in an unfavorable benefit-risk profile in a broad population. In t(11;14) pts, in addition to improvements in PFS, a positive trend in OS with Ven was observed, suggesting that a biomarker-driven approach with Ven may be most appropriate in MM.